Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v14-EN Version v9-FR
Language English French
Date Updated 2019-01-22 2019-01-11
Drug Identification Number 02360829 02360829
Brand name SPRYCEL SPRYCEL
Common or Proper name Dasatanib 140mg Dasatanib 140mg
Company Name BRISTOL-MYERS SQUIBB CANADA BRISTOL-MYERS SQUIBB CANADA
Ingredients DASATINIB DASATINIB
Strength(s) 140MG 140MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging size 1 BTL x 30 1 BTL x 30
ATC code L01XE L01XE
ATC description OTHER ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date 2019-01-21 2019-01-17
Actual start date 2019-01-21
Estimated end date 2019-01-21 2019-01-21
Actual end date 2019-01-21
Shortage status Resolved Anticipated shortage
Company comments Orders are being monitored / allocated. No other strengths are impacted. Orders are being monitored / allocated. No other strengths are impacted.
Health Canada comments